Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials

贝伐单抗 结直肠癌 危险系数 肿瘤科 医学 置信区间 内科学 子群分析 化疗 无进展生存期 随机对照试验 癌症 荟萃分析
作者
Daniele Rossini,Alessandra Boccaccino,Martina Carullo,Carlotta Antoniotti,Giovanni Dima,Paolo Ciracì,Federica Marmorino,Roberto Moretto,Gianluca Masi,Chiara Cremolini
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:184: 106-116 被引量:20
标识
DOI:10.1016/j.ejca.2023.02.006
摘要

Background Retrospective subgroup analyses of previous trials in the first-line therapy of RAS wt metastatic colorectal cancer (mCRC) suggested a predictive impact of primary tumour side on the efficacy of anti-epidermal growth factor receptor (EGFR) agents. Recently, new head-to-head trials of doublets/bevacizumab versus doublets/anti-EGFR, PARADIGM and CAIRO5 were presented. Patients and methods We searched for phase II and III trials comparing doublet chemotherapy plus an anti-EGFR or bevacizumab as the first-line treatment for RAS wt mCRC patients. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and radical resection rate result in the overall study populations and, according to the primary side, were pooled together in a two-stage analysis with random effects and fixed effect models. The interaction between sidedness and treatment effect was then analysed. Results We identified five trials (PEAK, CALGB/SWOG 80405, FIRE-3, PARADIGM and CAIRO5), including 2739 patients, 77% left- and 23% right-sided. Among patients with left-sided mCRC, the use of anti-EGFRs was associated with higher ORR (74% versus 62%, OR = 1.77 [95% confidence interval {CI} 1.39–2.26–0.88], p < 0.0001), longer OS (hazard ratio [HR] = 0.77 [95% CI 0.68–0.88], p < 0.0001) and not significantly longer PFS (HR = 0.92, p = 0.19). Among patients with right-sided mCRC, the use of bevacizumab was associated with longer PFS (HR = 1.36 [95% CI 1.12–1.65], p = 0.002) and not significantly longer OS (HR = 1.17, p = 0.14). A subgroup analysis confirmed a significant interaction effect between the primary tumour side and treatment arm in terms of ORR (p = 0.02), PFS (p = 0.0004) and OS (p = 0.001). No differences in the radical resection rate were found according to treatment and sidedness. Conclusions Our updated metanalysis corroborates the role of the primary tumour location in the choice of the upfront therapy for RAS wt mCRC patients, leading to strongly recommend anti-EGFRs in left-sided tumours and to prefer bevacizumab in the right-sided.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
潇洒冰蓝发布了新的文献求助10
刚刚
刚刚
2秒前
科研开门应助75986686采纳,获得10
3秒前
量子星尘发布了新的文献求助10
3秒前
卡卡荧光橙完成签到,获得积分10
4秒前
RYAN发布了新的文献求助30
4秒前
6秒前
通通完成签到,获得积分10
7秒前
7秒前
8秒前
Jasper应助bitahu采纳,获得10
8秒前
book发布了新的文献求助10
8秒前
fish完成签到,获得积分10
8秒前
shiyi应助苗条辣条采纳,获得10
9秒前
dwj发布了新的文献求助10
9秒前
jogrgr发布了新的文献求助10
11秒前
Holly12345应助榆术山支子采纳,获得10
12秒前
石会发发布了新的文献求助10
12秒前
迷人芙蓉发布了新的文献求助10
12秒前
潇洒冰蓝完成签到,获得积分10
12秒前
14秒前
tsntn完成签到,获得积分10
15秒前
知性的幻巧完成签到,获得积分10
15秒前
15秒前
橘子发布了新的文献求助20
16秒前
Eunhyo发布了新的文献求助10
16秒前
没有昵称发布了新的文献求助10
17秒前
李爱国应助sci一区采纳,获得10
18秒前
Jasper应助香蕉外套采纳,获得10
18秒前
19秒前
明理的霸发布了新的文献求助10
21秒前
21秒前
RYAN完成签到,获得积分10
21秒前
22秒前
bitahu发布了新的文献求助10
22秒前
Owen应助吃鸡腿吗采纳,获得10
22秒前
raoxray完成签到 ,获得积分10
23秒前
814791097完成签到,获得积分10
24秒前
淡然柚子发布了新的文献求助10
26秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975339
求助须知:如何正确求助?哪些是违规求助? 3519670
关于积分的说明 11199199
捐赠科研通 3256002
什么是DOI,文献DOI怎么找? 1798043
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305